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Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections worldwide,
yet no effective vaccine or antiviral treatment is available. Here we report the discovery and initial development
of RSV604, a novel benzodiazepine with submicromolar anti-RSV activity. It proved to be equipotent against
all clinical isolates tested of both the A and B subtypes of the virus. The compound has a low rate of in vitro
resistance development. Sequencing revealed that the resistant virus had mutations within the nucleocapsid
protein. This is a novel mechanism of action for anti-RSV compounds. In a three-dimensional human airway
epithelial cell model, RSV604 was able to pass from the basolateral side of the epithelium effectively to inhibit
virus replication after mucosal inoculation. RSV604, which is currently in phase II clinical trials, represents
the first in a new class of RSV inhibitors and may have significant potential for the effective treatment of RSV
disease.
Human respiratory syncytial virus (RSV) is the most impor-
tant respiratory pathogen that causes lower respiratory tract
infections, such as bronchiolitis and pneumonia, in infants and
young children, resulting in up to 125,000 hospitalizations an-
nually in the United States (3). The infants most at risk of
severe disease are those under 6 weeks of age, those with
bronchopulmonary dysplasia, congenital heart disease, or im-
munodeficiency, and those born prematurely. Hospital admis-
sion rates for these groups range between 5% and 30% (20,
25). The mortality rate among children admitted to hospital is
approximately 3% for those with heart and lung problems and
up to 1% for those without these risk factors (11, 25). In adults
and the elderly, RSV pneumonia is increasingly recognized as
a significant cause of morbidity and mortality, being associated
with more than 17,000 deaths annually between 1991 and 1998
(9, 22). Among the hospitalized elderly, mortality can be as
high as 10 to 20%, and among severely immunocompromised
patients with RSV pneumonia, it can be on the order of 50 to
70% (10). There is therefore an urgent and unmet medical
need for novel therapies to deal with infections caused by this
virus.
The development of new therapeutics for RSV was recently
reviewed (17, 19). Although research into the prevention and
treatment of RSV infection has been ongoing for almost 40
years, vaccine development is difficult (8, 13), and to date,
there is no clinically approved vaccine. The development of
RSV vaccines for use in young infants has been complicated by
reduced immune responses in this age group due to immuno-
logic immaturity and the immunosuppressive effects of mater-
nal antibodies. Passive immunization with the monoclonal an-
tibody palivizumab (Synagis) has provided about 50%
protection to high-risk children (21). These include infants
born prematurely and those with congenital conditions. Be-
cause the antibody has to be given prophylactically and treat-
ment is very expensive, its use is limited mainly to developed
countries. The effectiveness of ribavirin (16), the only licensed
antiviral small molecule against RSV, is questionable (24).
Ribavirin has to be given by prolonged aerosol and has been
shown to be potentially mutagenic and teratogenic. The need
for an effective and safe treatment for RSV infection is para-
mount.
RSV, a pneumovirus of the paramyxovirus family, is an en-
veloped nonsegmented negative-strand RNA virus (6). The
15.2-kb genome has been sequenced fully and contains 10
mRNA species encoding 11 distinct proteins. The genome is
encapsidated by the nucleocapsid (N) protein, which forms a
helical nucleocapsid and protects the RNA from ribonucleases.
The N protein is also associated with the viral polymerase,
phosphoprotein, and M2-1 protein, which together form the
transcriptase complex. The ribonucleoprotein (RNP) is essen-
tial for transcription, and naked RNA does not provide a
template for the viral polymerase. As with all single-stranded
RNA viruses, the virus does not have a proofreading mecha-
nism during replication, resulting in a relatively high error rate
and frequent mutations. Promising inhibitors targeting the fu-
sion event were unsuccessful, partly because of the rapid emer-
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gence of resistant mutants mapping to the F gene (5). There-
fore, an effective antiviral compound should ideally target
essential genes of the replication complex, as these are often
more highly conserved due to their functional role (19).
In this study, we describe the identification of RSV604, a
potent RSV inhibitor, and outline the experiments performed
to determine its mechanism of action (MOA). The results
suggest that RSV604 targets the nucleocapsid protein and is
active post-RSV infection. RSV604 is currently in phase II
trials.
MATERIALS AND METHODS
Cells and viruses. HEp-2 cells and RSV strains Long and B were obtained
from the American Type Culture Collection (Manassas, VA). Vero cells were
obtained from the European Collection of Cell Cultures (Porton Down, United
Kingdom). The RSV RSS and A2 strains and pneumonia virus of mice strain 15
were gifts from A. Easton (University of Warwick, United Kingdom). Bovine
RSV (Snook strain) was kindly supplied by G. Taylor (Institute of Animal
Health, Compton, United Kingdom). Cells and virus stocks were grown as
reported previously (4). Clinical isolates of RSV were obtained from G. Toms
(University of Newcastle, United Kingdom), P. Rice (St. Georges Hospital,
London, United Kingdom), J. De Vincenzo (University of Tennessee, Memphis,
TN), and the Health Protection Agency (Colindale, London, United Kingdom).
Synthesis of compounds. RSV604 and related compounds were synthesized as
previously described (4). BMS-433771 (5) was synthesized in-house. Ribavirin
was purchased from Sigma.
Antiviral assays. XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazo-
lium-5-carboxanilide, disodium salt; Sigma] assays were performed to assess the
protective effects of compounds on cell viability. Vero cells were used for the
primary screen of 20,000 compounds, and HEp-2 cells were used for all subse-
quent work. Plates (96-well) were seeded with 4  103 cells per well in Dulbec-
co’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum
(FBS). Cells were infected the next day with sufficient RSV (RSS strain) to
produce an approximately 80% cytopathic effect after 6 days. Cells were incu-
bated during this period in the presence or absence of serial dilutions of com-
pounds. The viability of cells was assessed after 6 days by using XTT. Only living
cells can reduce the tetrazolium salts into colored formazan products. Results
were expressed as 50% effective concentrations (EC50s) or 50% cell cytotoxicity
(CC50) values. Compounds were tested at an initial concentration of 10 M and
contained a concentration of 0.5% dimethyl sulfoxide (DMSO). To measure the
growth inhibitory effects of compounds on cells, a cell control (no virus) assay
was performed in parallel.
Effects on the expression of intracellular RSV antigen were evaluated by
enzyme-linked immunosorbent assay (ELISA). HEp-2 cells were seeded in 96-
well plates (5  103 cells per well in DMEM containing 10% FBS) for 24 h. Cells
were infected at a multiplicity of infection (MOI) of approximately 0.02 and
incubated in the presence or absence of serial dilutions of compound for 3 days.
Cells were then fixed and permeabilized with 75% methanol–25% acetone and
blocked with 2% nonfat milk (Marvel)–0.05% Tween. Plates were then incu-
bated in the presence of a mouse anti-RSV monoclonal antibody (NCL-RSV3;
Novocastra) followed by a rabbit anti-mouse horseradish peroxidase-labeled
secondary antibody (DAKO). The plates were developed with O-phenylenedi-
amine in the presence of hydrogen peroxide, and absorbance was measured at a
wavelength of 650 nm using a plate reader.
Plaque reduction assays were carried out by infecting HEp-2 cell monolayers
with 0.2 ml of 500 PFU/ml of RSV (RSS strain) per well of a six-well plate. After
2 h, cells were overlaid with DMEM containing 2% FBS and 0.6% agarose and
compounds were added from a dilution series. Plates were incubated for 5 days
and fixed with 10% formaldehyde. The agarose plugs were removed, and viral
plaques were visualized by methylene blue staining or immunostaining. Plaques
were counted, and results were expressed as percentages of virus replication
compared with the plaques counted on wells infected in the absence of inhibitor.
Generation and sequencing of resistant viral mutants. HEp-2 cells were in-
fected with RSV strain RSS (MOI, 0.01) and grown in the presence of compound
until the cytopathic effect reached approximately 80 to 90%. Virus was harvested
and used to reinfect cells in a similar manner. A starting dilution corresponding
to 0.5 EC50 was used for the first passage, and at each passage, the compound
concentration was either kept constant or doubled until a resistant mutant was
isolated and its resistance verified by cell ELISAs and plaque reduction assays,
using a DMSO-passaged wild-type (WT) virus as a control. Resistant mutants
were then plaque picked three times under agarose. Total RNA was prepared
from infected cell pellets and reverse transcribed into cDNA according to the
Thermoscript protocol (Invitrogen, Paisley, United Kingdom), using random
primers. Overlapping 1-kb DNA fragments covering the whole RSV (RSS)
genome were amplified using a high-fidelity DNA polymerase (ThermalAce;
Invitrogen). PCR conditions were 94°C for 1 min followed by 30 cycles of 94°C
for 1 min, 50°C for 1 min, and 72°C for 1 min. PCR products were purified and
sequenced directly using a Beckman CEQ-2000 capillary sequencing system.
Resistant RSV sequences were aligned against the RSS strain (GenBank acces-
sion number U39662).
Reverse genetics. Reverse genetic experiments were carried out as previously
described (7). A QuikChange II XL site-directed mutagenesis kit (Stratagene)
was used to introduce the following changes into the RSV antigenome plasmid
(7): A313G, A385T, C415A, and A385T with C415A. The base numbers refer
to those for the N open reading frame (the initiating ATG bases are num-
bered 1 to 3).
Recovered recombinant virus was propagated in HEp-2 cells, tested against
RSV604 and A-33903 by plaque reduction assays, and compared to WT virus. An
M2-2 gene deletion RSV mutant (2) was also tested as a control. Each of the
recombinant viruses was sequenced in its entirety to ensure that no other mu-
tations were introduced.
HAE cell culture model. Human airway epithelial (HAE) cells were isolated
and cultured as previously described (26). Briefly, human nasal, tracheobron-
chial, and bronchial airway epithelial cells were isolated and seeded on collagen-
coated permeable membrane supports. Once the cells were confluent, the apical
medium was removed and cells were maintained at the air-liquid interface for
approximately 4 to 6 weeks to allow epithelial differentiation. Cultures contain-
ing ciliated cells and transepithelial resistances of 300 /cm2 were inoculated
via the luminal surface with a recombinant RSV expressing green fluorescent
protein (GFP), named rgRSV (14). Infection was monitored by visualization of
GFP with a fluorescence microscope. Compounds at various concentrations were
added to the basolateral medium concomitantly with the virus.
RESULTS
Identification of RSV604. A selection of approximately
20,000 compounds from the Arrow Therapeutics corporate
collection were screened in a single-concentration (10 M),
cell-based XTT assay to identify active compounds that inhib-
ited any target involved in virus replication. Compounds iden-
tified in this way exhibited potential antiviral activity and were
rescreened at various concentrations appropriate for each
compound to calculate an EC50 or CC50 value, defined as a
50% reduction in virus- or compound-induced cell death, re-
spectively.
A number of compound classes with good therapeutic ratios
(50) were discovered. Selected compounds from each class
were further tested against four different RSV strains in cell-
based ELISAs and plaque reduction assays, which subse-
quently led to the selection of a lead compound, A-33903
(Table 1). This compound was chosen as a starting point for
the synthesis of over 650 analogs. Continuous iterative cycles
of synthesis, biological profiling, and modeling techniques ul-
timately resulted in the identification of the clinical candidate
RSV604. Selected examples that illustrate the process of opti-
mization are shown in Table 1. A detailed study of the struc-
ture-activity relationship for the chemical series was recently
described by Carter et al. (4).
Physical and chemical properties of RSV604. The systematic
name of RSV604 within the IUPAC nomenclature is (S)-1-(2-
fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]di-
azepin-3-yl)-urea, with the sum formula C22H17FN4O2 and a
molar mass of 388.4 g/mol. The compound is a white powder
which is stable at room temperature and has a melting point of
243 to 245°C (decomposition).
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Profile of RSV604. The first identified compound of the
selected series, A-33903, a racemic mixture, showed moderate
activity against four laboratory strains of RSV, and no associ-
ated toxicity was observed in the XTT assay with concentra-
tions of up to 50 M. It was approximately 2.5 times more
active than ribavirin in cell ELISA (Table 1). An early deriv-
ative, A-57400, showed improved activity but also showed
some growth inhibitory effects at 50 M. Separation of the two
isomers of A-33903 demonstrated that the antiviral activity was
associated with the S enantiomer (15). Therefore, all subse-
quent compounds of this series tested were the isolated S
enantiomers. The EC50 of the optimized compound RSV604
was determined to be 0.5 to 0.9 M by plaque reduction assay.
Similar activities were also observed in XTT assays and cell
ELISA (Table 1). RSV604 exhibited a therapeutic ratio of 58
(limited by solubility) and was at least 15 times more potent
than ribavirin.
Increasing the MOI of RSV from 0.02 to 1.5 had only a slight











RSS Long A2 B
RSV604 0.86  0.02 1.7  0.7 0.9  0.3 0.8  0.1 0.5  0.1 0.6  0.2 50 58
A-33903 9.6  1.4 10.1  3.7 9.7  5.5 7.2  2.7 15.1  4.4 3.5  0.2 50 5
A-57400 3.0  0.9 1.1  0.3 1.4  0.6 1.2* 1.2  1.1 NDc 50 16
A-60445 0.9  0.2 0.5* 0.8* 0.57  0.15 NDc 0.23  0.05 50 55
A-64315 0.5  0.1 1.3  0.7 0.5* 0.39  0.04 ND 0.43  0.1 50 100
Ribavirin 11.5  2.1 25.3  8.6 13.3  2.2 16.8  1.8 19.0  0.9 29.0  19.0 NDc NDc
a Data are means  SD for at least three independent experiments unless otherwise indicated (*, data are for one experiment). The XTT assay measures the ability
to inhibit RSV-induced cell death. The cell ELISA measures the ability to reduce viral antigen synthesis in RSV-infected cells.
b Measured by XTT assay (n  2).
c ND, not determined.
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effect on the EC50 of RSV604 (EC50  1.4 and 2.55 M,
respectively). RSV604 was also active against bovine RSV
(EC50  0.3 M in the plaque reduction assay), but no activity
was observed against pneumonia virus of mice, parainfluenza
virus type 1 (PIV1), PIV3, and human metapneumovirus (all
with EC50s of 50 M), with the latter being the human
respiratory virus most closely related to RSV. Importantly,
RSV604 was also equipotent against 40 clinical isolates of
RSV, with an average EC50 of 0.8  0.2 M by plaque reduc-
tion assay (Fig. 1). Clinical isolates covered both the A and B
subtypes, a 15-year span of infections, and the northern and
southern hemispheres. None of the clinical isolates tested
showed any resistance to RSV604, as demonstrated by the
narrow range of EC50 values determined.
MOA. RSV604 was able to inhibit virus replication at similar
levels when given prior to infection and at up to 6 h postin-
fection (Fig. 2A). These data strongly suggest that RSV604
acts at a step subsequent to adsorption and viral penetration.
In contrast, BMS-433771, a known fusion inhibitor (5), was
most active when given prophylactically or concurrently with
the virus. It was less active when given at 6 h postinfection (Fig.
2B). The timing with which RSV604 was active is consistent
with effects on viral transcription and/or RNA replication.
The MOA of antiviral compounds is often examined
FIG. 1. RSV604 EC50 values for 40 clinical isolates of RSV. The antiviral effect of RSV604 was investigated with 40 clinical isolates of RSV
by plaque reduction assay, and EC50 values (M) were calculated. The overall mean EC50 value (thick line)  standard deviation (SD) (thin lines)
of the 40 isolates is shown. Isolates 1 to 6 are from Hong Kong, isolates 7 to 18 are from Argentina, isolates 19 and 20 are from Qatar, isolates
21 to 30 are from Europe, and isolates 31 to 40 are from the United States. RSV-A strains are denoted by filled diamonds, and RSV-B strains are
denoted by open diamonds.
FIG. 2. Antiviral effect of delayed addition of inhibitor. Dose-dependent anti-RSV activities of RSV604 (A) and the fusion inhibitor BMS-
433771 (B) were determined in vitro by plaque reduction assay; compounds were added either 2 h prior to infection (2 h) or at 6 h postinfection
(6 h). The mean of duplicate wells per compound dilution was used to calculate the percent plaque reduction compared to compound-free,
virus-infected control wells. Results shown are the means and SD for four independent experiments.
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through the generation of drug-resistant mutants. Mutants to
RSV604 and A-33903 were isolated after multiple passages of
virus with increasing concentrations of the compounds. An
approximately eightfold increase in the cell ELISA-based EC50
was observed for the RSV604 mutant after eight passages
compared to that for DMSO-passaged WT virus. This was
confirmed by plaque assay, where a 10-fold resistance was
observed. Three subsequent rounds of plaque picking at pas-
sage 8 (in the presence of 25 M drug) resulted in a virus that
had 40-fold resistance to RSV604 in comparison to the con-
trol virus in both the cell ELISA and plaque assay (Table 2).
Resistance against A-33903 emerged at passage 5 (in the pres-
ence of 32 M of compound), showing a twofold increase in
the EC50 by cell ELISA compared to that for DMSO-passaged
WT strain RSS. Resistance was confirmed at passage 6 (max-
imum concentration of 64 M, or eight times the EC50) by cell
ELISA and plaque reduction assay, showing about twofold and
fourfold resistance, respectively. Three subsequent rounds of
plaque picking at passage 6 resulted in a resistant virus that
had a fourfold increased resistance to A-33903 in comparison
to the control virus by plaque reduction assay (Table 2). The
plaque-picked mutants were found to be cross-resistant to
other compounds within the same chemical series (A-60445
and A-64315), indicating that the MOAs throughout the series
are similar. Mutants did not show resistance to either ribavirin
or a fusion inhibitor (A-57156), implying a different MOA for
these compounds (Table 2).
Sequencing of the complete genomes of the plaque-picked
resistant viruses and the corresponding DMSO-passaged WT
virus revealed mutational changes in the conserved N-terminal
region of the nucleocapsid protein only (amino acids 105 to
139). The N gene of RSV was also sequenced from viruses
obtained from the passages immediately prior to plaque pick-
ing. The amino acid substitutions identified were as follows:
N105D in the A-33903-resistant RSV from passages 5 and 6
and the plaque-purified virus, K107N with I129L in the
RSV604-resistant virus prior to plaque purification (passage
8), and I129L with L139I in the plaque-purified RSV604-resis-
tant virus. The alignment of WT RSV sequences shows that
these residues are conserved across RSV strains (Fig. 3). No
additional mutations were identified in any of the other RSV
genes.
Reverse genetic experiments were carried out to confirm
that these mutations were responsible for the observed resis-
tance profile. The following base changes were individually
introduced into the N gene of the A2 antigenome plasmid:
A313G, A385T, C415A, and A385T with C415A. These make
the following amino acid changes in the N protein: N105D,
I129L, L139I, and I129L with L139I, respectively. Recombi-
nant viruses were generated and analyzed. The resulting mu-
tant viruses all showed resistance to RSV604 compared to the
WT control (Fig. 4; Table 3). The levels of resistance were
between 5-fold and 7-fold for the single mutants and 20-fold
for the double mutant (Table 3). Each of the mutant genomes
was fully sequenced, confirming the role of the mutations in
the resistance profile. As an additional control, we also evalu-
ated an attenuated RSV mutant in which the WT virus se-
quence had been modified by the introduction of point muta-
TABLE 2. Cross-resistance profiles of RSV604- and
A-33903-resistant mutants
Compound



















RSV604 0.6 30.4 50.7 0.7 2.7 3.9
A-33903 8.1 100 12.3 8.9 27.6 3.1
A-60445 ND ND ND 0.4 1.3 3.3
A-64315 0.4 16.9 42.3 ND ND ND
A-57156c 	0.16 	0.16 
1 	0.16 	0.16 
1
Ribavirin 20.7 17.6 0.85 ND ND ND
a Determined by plaque reduction assay. A plaque-picked RSV604 mutant
from passage 2 and a plaque-picked A-33903 mutant from passage 2 were tested
for sensitivity to the indicated compounds. ND, not determined.
b Increase in resistance of the mutant compared to its WT virus control.
c Fusion inhibitor.
FIG. 3. Mapping of resistance to RSV604 to the nucleocapsid protein. A partial sequence alignment (from amino acids 1 to 240) for the N
proteins from the human RSV strains A2 (Protein Data Bank [PDB] no. AAB59852.1), RSS (PDB no. NP044591.1), and subgroup B (PDB no.
AAB82431.1) is given. Amino acid sequence identities in all three strains are denoted by asterisks. The positions of amino acid changes observed
for the resistant mutants derived against RSV604 and A-33903 are given in bold and denoted with daggers.
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tions into the M2-2 open reading frame (2). As expected, this
virus (designated M-2) was equivalent to WT RSV in its sen-
sitivity to RSV604 (Fig. 4). Growth curves were performed to
assess the overall fitness of the mutant viruses. There was no
significant difference in the replication of the mutant viruses
compared to that of the WT (data not shown).
RSV604 inhibits RSV infection in a model of HAE. Due to
the lack of small animal models of the HAE, in which human
RSV infects and replicates efficiently (19), the antiviral activity
of RSV604 was tested in a well-characterized in vitro model of
differentiated HAE that recapitulates the morphology and
physiology of the HAE in vivo. This model has previously been
shown to support efficient infection, replication, and spread of
a number of human respiratory viruses, including RSV (26). In
this study, the apical surface of HAE was inoculated with a
recombinant, GFP-expressing RSV (rgRSV; 106 PFU) and
RSV604 was concomitantly added to the medium on the ba-
solateral surface. RSV604 was able to block virus replication,
as judged by the lack of green fluorescence, when given at a
concentration of 2 M. A dose of 1 M inhibited virus repli-
cation approximately 50% (Fig. 5). Similar values were ob-
tained with RSV604-treated RSV-infected HEp-2 cells (EC50 
0.5 to 0.9 M) (Table 1). Concentrations of 10 and 20 M
RSV604 completely blocked infection. RSV604 was at least
20-fold more active than ribavirin in inhibiting RSV replication
in the HAE model (Fig. 5). Adding RSV604 (2, 10, or 20 M)
as late as 24 h postinfection resulted in a lack of green fluo-
rescence, indicating inhibition of viral spread. No gross cyto-
toxicity, leakage of basolateral fluid to the apical surface, or
alteration of cilium beat frequency was observed when HAE
cultures were exposed to 20 M RSV604 for 7 days.
DISCUSSION
Given the barriers to progression of an effective and safe
RSV vaccine, the development of an orally active small-mole-
cule drug which is virus specific and hence safe, potent, and
effective is urgently needed.
We have identified a novel series of RSV inhibitors through
the use of a well-selected library designed for antiviral screen-
ing containing only compounds that have the potential for
further development. The current study shows that the lead
compound from this series, RSV604, exhibits all of the above
properties. RSV604 displays submicromolar activity against
numerous clinical isolates of both the A and B subtypes of
RSV, indicating a low probability of preexisting resistance mu-
tations in the population. Unlike other promising inhibitors
which mainly target the fusion event (19), RSV604 is active
when given postinfection. Moreover, a significant reduction in
viral spread was shown in an HAE cell model when RSV604
was given as late as 24 h postinfection.
The ability to rapidly generate resistant mutants in vitro,
even at high concentrations of inhibitor (over 1,000 EC50),
has posed a major problem for the development of an effective
RSV drug in the past. The generation of fusion inhibitor-
FIG. 4. Sensitivities of WT and RSV mutant viruses to RSV604. Dose-dependent anti-RSV activities of RSV604 were determined by plaque
reduction assay. Results are representative of three independent experiments. Mean EC50 values ( SD) for RSV604 against WT and mutant
viruses can be found in Table 3.
TABLE 3. Sensitivities of recombinant mutant viruses to RSV604
Virus RSV604 EC50 (M)a
Fold increase in
resistanceb
WT 0.96  0.04 1.0
M2 1.14  0.41 1.2
N105D mutant 4.78  0.93 5.0
I120L mutant 6.03  0.50 6.3
L139I mutant 6.70  0.80 7.0
I129L-plus-L139I mutant 20 20
a Data are means  SD for three separate plaque reduction assays.
b Compared to the WT virus control.
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resistant mutants can be accomplished after several passages
and may arise after only a single passage (5). In this study, the
generation of mutants resistant to RSV604 was slow in com-
parison. It took eight passages in the presence of RSV604
before a resistant virus emerged. Without a suitable animal
model of infection for the study of RSV replication inhibitors,
we have been unable to characterize the replication of these
resistant viruses in vivo. However, in vitro growth studies
showed that the overall fitness of the mutant viruses engi-
neered by reverse genetics was similar to that of the WT virus.
Sequencing revealed that the mutations in RSV604-resistant
RSV mapped to the highly conserved nucleocapsid (N) pro-
tein. Reverse genetic experiments showed that when these
mutations were introduced, alone or in combination, the re-
sulting recombinant viruses were resistant to the effects of
RSV604. This suggests that the N protein is a bona fide mo-
lecular target of RSV604. The N protein is a highly conserved
major structural protein that is involved in encapsidation of the
RNA genome and is essential for replication and transcription
(6). The structures of the N proteins from two negative-strand
viruses, vesicular stomatitis virus (12) and rabies virus (1), have
recently been reported. In the case of these two viruses, the N
protein is composed of two domains, with the single-stranded
RNA molecule bound in a cavity at the interface. The two
domains clamp down on the RNA and protect it from the
surrounding environment. There is no crystal structure avail-
able for the RSV N protein, but further insight into RSV RNP
complexes was recently provided by Tran et al. (23). The N
protein assembles in an annular, multimeric complex of 10 or
11 subunits, with each subunit contacting six nucleotides. We
are currently aiming to obtain a high-resolution (	3 Å) image
of the structure of the RSV N protein to better predict what
effects the mutations outlined in this study have on the protein
and its interactions with other viral proteins. In particular, we
will investigate the interaction between the N and P proteins.
Murphy et al. suggested that amino acids 121 to 160 of the
RSV N protein may be important for maintaining helical sta-
bility (18). The RSV604-resistant mutants had amino acid sub-
stitutions within this region which were shown to be important
for resistance. With such a pivotal role in replication and tran-
scription, it is highly likely that any effect on the N protein
structure or function would be detrimental to the virus. This
makes the N protein an excellent antiviral target.
In vivo studies with potential RSV inhibitors have been
hindered by the lack of a suitable small animal model. The use
of mice and cotton rats to study various aspects of RSV disease
has been described previously; however, virus titers of up to
107 PFU are needed to infect these animals and the amount of
virus recovered from the infected tissues is relatively low. This
strongly suggests that replication in these animals is highly
restricted. These models have been used successfully to study
RSV monoclonal antibodies and potential fusion inhibitors
whose effectiveness does not rely on active virus replication,
but they are clearly unsuitable for the current study. To par-
tially overcome this challenge, a three-dimensional HAE
model was used in this investigation. This model was previously
shown to support RSV replication specifically in ciliated cells
after luminal inoculation, with exclusive apical shedding of
progeny virions that are subsequently spread by the coordi-
nated motion of the beating cilia. RSV604 administered to the
basolateral medium was able to penetrate the multilayered
epithelium of these cultures in sufficient amounts to effica-
ciously inhibit viral replication and spread. This indicates that
the systemic delivery of this compound will be useful against
luminal RSV infection.
A preclinical safety program was performed to assess the
safety profile of RSV604 before commencing early studies in
humans. It was concluded that RSV604 was well tolerated by
all species tested, and an evaluation of the major organ systems
in vivo demonstrated that there were no effects attributable to
treatment. These promising preclinical data have enabled the
study of the drug in phase I trials, where volunteers have been
exposed to increasing quantities of RSV604. These studies
show that the drug is well absorbed in humans, and the human
FIG. 5. Dose-dependent inhibition of RSV replication in an in
vitro model of human ciliated epithelium. RSV replication was mea-
sured visually by the expression of GFP from the virus genome (21).
The top two panels show control cultures in the absence of drug.
Compound (RSV604 or ribavirin) was added to the basolateral me-
dium concomitantly with the virus at the concentrations indicated.
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pharmacokinetics support once-a-day dosing to achieve antivi-
ral EC90 levels.
In conclusion, we have identified a novel, safe, and highly
potent small-molecule inhibitor that targets the replication
complex of RSV and constitutes the most promising candidate
to date for the treatment of RSV disease in humans. Phase II
clinical trials are under way to validate the effectiveness of
RSV604 in treating RSV infection in the clinic.
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